Modulation of the tumor microenvironment by the TLR9 agonist EnanDIM and combination with checkpoint inhibition for cancer immunotherapy

被引：0
|
作者：
Kapp, K. [1 ]
Volz, B. [1 ]
Oswald, D. [1 ]
Wittig, B. [2 ]
Schmidt, M. [1 ]
机构：
[1] Mologen AG, Translat Res, Berlin, Germany
[2] Free Univ Berlin, Fdn Inst Mol Biol & Bioinformat, Berlin, Germany
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
56P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Combination of TLR9 agonists EnanDIM with checkpoint inhibitors for cancer immunotherapy
    Schmidt, Manuel
    Kapp, Kerstin
    Oswald, Detlef
    Wittig, Burghardt
    Volz, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [2] Modulation of checkpoint expression in tumor microenvironment by intratumoral administration of a novel TLR9 agonist: Rationale for combination therapy
    Jiang, Wayne
    Wang, Daqing
    Zhu, Fugang
    Bhagat, Lakshmi
    DiMuzio, Jillian
    Agrawal, Sudhir
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
  • [3] Preclinical data of novel enantiomeric oligonucleotides for cancer immunotherapy: The TLR9 agonist EnanDIM
    Kapp, Kerstin
    Volz, Barbara
    Oswald, Detlef
    Wittig, Burghardt
    Schmidt, Manuel
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)
  • [4] Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy
    Wang, Daqing
    Jiang, Wayne
    Zhu, Fugang
    Mao, Xianzhi
    Agrawal, Sudhir
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2018, 53 (03) : 1193 - 1203
  • [5] The TLR9 Agonist EnanDIM® - Evaluation of New Enantiomeric Oligonucleotides for Cancer Immunotherapy In Vitro and In Vivo
    Kapp, Kerstin
    Schroff, Matthias
    Wittig, Burghardt
    Schmidt, Manuel
    MOLECULAR THERAPY, 2016, 24 : S292 - S292
  • [6] Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors
    Kapp, Kerstin
    Volz, Barbara
    Oswald, Detlef
    Wittig, Burghardt
    Baumann, Matthias
    Schmidt, Manuel
    ONCOIMMUNOLOGY, 2019, 8 (12):
  • [7] Combination of TLR9 agonist lefitolimod/MGN1703 with checkpoint inhibitors for cancer immunotherapy.
    Schmidt, Manuel
    Kapp, Kerstin
    Volz, Barbara
    Oswald, Detlef
    Wittig, Burghardt
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [8] Immunomodulation and inhibition of tumor growth by a new class of TLR9 agonists - EnanDIM
    Volz, B.
    Kapp, K.
    Oswald, D.
    Wittig, B.
    Schmidt, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Two new TLR9 agonists for cancer immunotherapy: Combination with checkpoint inhibitors
    Kapp, Kerstin
    Volz, Barbara
    Oswald, Detlef
    Wittig, Burghardt
    Schmidt, Manuel
    CANCER RESEARCH, 2017, 77
  • [10] Evaluation of new TLR9 agonists for immunotherapy: Enantiomeric oligonucleotides (EnanDIM®)
    Kapp, K.
    Schmidt, M.
    Wittig, B.
    Schroff, M.
    Kleuss, C.
    EUROPEAN JOURNAL OF CANCER, 2016, 55 : S9 - S9
12345